Is Tumor Mutational Burden Really ‘Ready for Primetime’ as a New Immunotherapy Biomarker? – Medscape
|
Is Tumor Mutational Burden Really 'Ready for Primetime' as a New Immunotherapy Biomarker?
Medscape H. Jack West, MD: Hello. I'm Jack West, medical director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle. Welcome to Medscape Oncology Insights. Joining me today is Hossein Borghaei, chief of thoracic medical oncology at Fox … |
